Introduction
Calcium antagonists block the influx of calcium ions through voltage-operated calcium channels located in the cell membrane. Among the different groups, dihydropyridines are the most numerous and include the largest number of novel compounds. They act upon the L-type channel, which has a specific dihydropyridine site in its extra cellular surface and bind more selectively to vascular calcium channels than to those in the myocardium. Newer dihydropyridines exhibit greater selectivity, with evidence for specific vascular vessel bed binding. Each of these agents is effective in the treatment of hypertension and angina pectoris [1] [2] [3] .
The therapeutic importance of dihydropyridines initiated several reports on its determination, both in formulations and in biological fluids, viz: spectrofluorometric [4] , spectrophotometric [5, 6] , voltammetric [7] [8] [9] [10] [11] , amperometric [12] thin-layer chromatographic [13] , capillary gas chromatographic [14] and high-performance liquid chromatographic [15] [16] [17] .
The compounds studied were: nicardipine (NIC) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)methyl-2-[methyl(phenyl methyl)amino]-3,5-pyridinedicarboxylic acid ethyl ester, nifedipine (NIF) 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine-dicarboxylic acid dimethyl ester and isradipine (ISRA) 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid methyl 1-methylethyl ester. The formulas of these drugs are shown in Fig. 1 .
The aim of this work is to develop a simple and sensitive method for determination of NIC, NIF and ISRA in pure, pharmaceutical preparations and biological fluids. The proposed method is based on the fact that the 1,4-DHPs under study have no native fluorescence in spite of the presence of a dihydropyridine ring structure which imparts strong fluorescence characteristics to the compound containing it [18] . This is due to the strong quenching effect of the nitro group or furazan ring. Reduction of these groups to the corresponding amino group enables the studied 1,4-DHPs to retain their strong fluorescence. The addition of some surfactants substantially enhanced the fluorescence produced. The proposed method has been applied for the fluorimetric determination of the studied compounds in biological fluids. The most striking advantage of the proposed method is that no prior extraction step is necessary when applied to urine. The results obtained are promising.
Experimental Procedures

Apparatus
A FP-750 JASCO-PC Spectrofluorometer with a Xenon arc lamp, and 1cm quartz cells, were used all over the measurements.
Materials
Nicardipine hydrochloride was obtained from Sigma chemical co. (St. Louis, MO, USA), nifedipine hydrochloride was kindly supplied by Bayer (Wuppertal, Germany), Isradipine was graciously gifted by Novartis Pharma (Basle, Switzerland). The isradipine tablets (Lomir tablets) contained 2.5 mg of isradipine per tablet (Novartis Pharma, AG, Basle, Switzerland), while the nifedipine tablets (Adalat retard tablets) contained 20 mg of nifedipine per tablet (Pyaer, Allemagne, Germany), and the nicardipine capsules (Pelcard capsules) contained 50 mg of nicardipine per capsule (Global Napi Pharmaceuticals, Egypt).
Stock solutions
Solutions containing 20 mg/100 ml of the studied drugs were prepared in methanol. Diluted solutions were obtained using the same solvent.
Reagents
Zinc powder and Hydrochloric acid solution 36.5-38% (1M) were obtained from BDH (Poole, UK). Ammonium chloride (1M) (BDH, Poole, UK) was prepared by dissolving 5.35 g in doubly distilled water and made up to 100 ml.
Formic acid 98-100% (1M) was obtained from Merck (Germany). Plasma was kindly provided by King Fahd Military Medical Complex (Dhahran, Saudi Arabia) and kept frozen until the assay, when it was gently thawed. Urine was obtained from healthy volunteers (males between 25-30 years old).
Procedure
Preparation of calibration graphs
Aliquots containing drugs within the concentration ranges cited in Table 1 were transferred into a set of 25 ml standard flasks. Complementary volumes of methanol were introduced to adjust the volume to 5 ml, and 1 ml of CMC (0.5% w/v) for nifedipine and isradipine or 1 ml of SDS (1% w/v) for nicardipine were added. 0.45 g of zinc powder and 1-3 ml of 1 M HCl were added to each flask. The volume was completed to the mark with distilled water and the reaction mixture was left to stand for 15 min at room temperature. This mixture was then filtered through a dry filter paper and the fluorescence intensity of the filtrate was measured at the suitable λem/ λex, depending on the drug. A blank reagent without the drug was measured simultaneously. Calibration graphs were constructed by plotting the fluorescence intensity versus the final concentration (μg ml -1 ) of the drugs. Alternatively, the regression equations were derived.
Procedure for pharmaceutical preparations
Ten tablets of the drugs were finely powdered and thoroughly mixed. Accurately weighed amounts equivalent to 20 mg of drug were transferred to a small flask; 20 ml of methanol was added, gently mixed for 3-4 min and filtered into a 50 ml volumetric flask with few ml of methanol; also the washings were passed to the same flask. The volume was completed with methanol. An aliquot of this solution was analyzed according to the procedure cited before in 2.4.1. A blank reagent without the drug was measured simultaneously. The content of the tablets were determined either from the calibration graph or the regression equation.
Procedure for spiked urine
1.0 ml aliquots of urine were transferred into a series of 25 ml standard flasks. Aliquots from the stock solution of drug were added so that the final concentration is in the range cited in Table 1 . These solutions were analyzed according to the procedure cited before in 2.4.1. A blank sample using urine without the drug was measured simultaneously. The content of the drug was calculated either from the calibration graph or the regression equation.
Procedure for spiked plasma
1.0 ml aliquots of plasma were transferred into a set of centrifugation tubes. Aliquots from the drug stock solution were added so that the final concentration is in the range cited in Table 1 . The solution was mixed thoroughly using a votex mixer. 0.1 ml of ethanol, 1.0 ml of 0.1 M borate-hydrochloric acid buffer (pH 9.0), and 4 ml of n-hexane/ethyl acetate (92.5:7.5 v/v) were added to each tube and gently mixed for 5 min. and centrifuged at 2800 rpm for 15 min. The organic phase was then transferred to a set of small beakers and evaporated under a stream of nitrogen. The residue was dissolved in 5 ml methanol and then analyzed according to the procedure cited before in 2.4.1. A blank sample using plasma without the drug was measured simultaneously. The content of the drug was calculated either from the calibration graph or the regression equation.
Results and Discussion
The reduction of NIC, NIF and ISRA with zinc in hydrochloric acid was found to give a strongly fluorescent product owing to the fluorescene enhancing structural changes in the dihydropyridine ring that originally exhibits a strong yellow green fluorescence [18] . Upon reduction, the nitro group is reduced into the corresponding amino group [19] . In addition, depending on the presence of the furazan ring structure in isradipine, the following pathway reaction may be postulated (Scheme 1) [8] :
The presence of the primary amino groups increases the fluorescence of the drug due to their electron donating effect that produces a high degree of resonance stability in the multiple conjugated double bonds of the drug molecule. The high degree of resonance stability enhances the fluorescence via delocalization of the π-electrons that can be placed in low lying excited singlet states, which results in increase in the transition probability between the lowest excited singlet-state and the ground state [20] . The reduction process is proposed to proceed as shown above. The formed fluorophore exhibits strong fluorescence for nicardipine, nifedipine and isradipine at λ em /λ ex of 460/364, 450/393 and 446/360 nm, respectively, as shown in Fig. 2. 
Optimization of the Parameters
The reaction conditions with respect to the amount of Zn powder, the volume of 1 M HCl and the reaction time at constant temperature were optimized to achieve maximum fluorescence. The first goal was to choose the most appropriate reduction system. The fluorescence intensities of the solutions as a function of reducing reagents were compared. The reduction systems investigated were: Zn/HCl, Zn/NH 4 Cl and Zn/formic acid. Of all the reducing agents, the highest fluorescence intensity was observed with 0.45 g of Zn powder. The fluorescence of the solutions was investigated over a hydrochloric acid (1 M) volume range of 1-7 ml. The optimum fluorescence was achieved using 1-3 ml. The effect of time on the development of the fluorescence Figure 2 . Fluorescence spectra of isradipine (1μg ml Table 1 . Analytical performance data of the proposed spectroflourometric method for nifedipine, nicardipine and isradipine in pure form. product and its stability was studied. The reaction product was formed immediately, and was observed to reach maximum development after 15 min at room temperature and remained stable for more than 4 hours. The effect of temperature was studied, wherein the fluorescence intensities of the solutions were decreased over a temperature range of 40-100ºC. In order to examine the effect of macromolecules surfactants with concentrations of 1% w/v of β-cyclodextrine (βCD), sodium dodecyl sulphate (SDS), Triton x-100 and 0.5% carboxymethylcelullose (CMC), on the fluorescence intensities of the reduced drugs, their volumes were investigated over the range of 1-6 ml. From the results, it is evident that the addition of SDS (1% w/v) for nicardipine or CMC (0.5% w/v) for isradipine and nifedipine gave the highest readings, and therefore, it was used throughout the study.
Validation of the method
The method was tested for linearity, precision, reproducibility and specificity. By using the above fluorometric method, a linear regression equation was obtained. The regression plot showed that there was a linear dependence of the relative fluorescence intensity on the concentration of the drugs in the ranges shown in Table 2 . Statistical evaluation of the regression lines gave values such as: Standard deviation of the residuals (S y/x ), standard deviation of the intercept (S a ), standard deviation of the slope (S b ) and relative standard deviation, which are shown in Table1. The good linearity of the calibration graph and the negligible scatter of the experimental points are clearly evident by the correlation coefficient (close to 1). The quantification limits (10 S a /slope) and detection limits (3 S a / slope) were calculated ( Table 1) . The specificity of the method was investigated by observing any interference encountered from the excipients of the tablets mass. It was shown that these compounds do not interfere with the proposed method ( Table 3) . At the same time because of the dependence of the reaction on the presence of the dihydropyridine nucleus in the drug molecule, the degradation product (pyridine derivative) does not interfere. The robustness of this method is demonstrated by the versatility of the experimental factors that affect the fluorescence intensity.
Analytical Applications
Regression analysis of the data indicated a linear relationship between fluorescence and concentration (μg ml performance of the two methods regarding the accuracy and precision, respectively, as shown in Table 2 . This method was further applied to the determination of the three compounds in tablets. Table 3 shows the recoveries of the different concentrations of the compounds, wherein the results obtained are in good agreement with those obtained from the officials or reference methods. Statistical analysis of the results obtained show no significant difference between the performance of the two methods regarding accuracy and precision using student's t test and the variance ratio F test.
Analysis of Biological Fluids
The high sensitivity of the proposed method however, allows the determination of nicardipine, nifedipine and isradipine in spiked human plasma and urine. A dose of 30 mg nifedipine, 50 mg nicardipine and 5 mg daily isradipine are orally administered. The anticipated concentration in biological fluids will be about 0.6, 1.0 and 0.12 μg ml -1 for nifedipine, nicardipine and isradipine, respectively, which lies within the working concentration range of the proposed method. The application of the method for plasma was performed adopting the extraction procedure described [24] . As for urine, the method was successfully applied without prior extraction. The results obtained in Table 4 are satisfactorily accurate and precise.
Since the pathway of degradation of the dihydropyridine derivatives is the oxidation of the dihydropyridine ring to pyridine [25] and also because the dihydropyridine ring is essential for both the pharmacological action of the drug, and the fluorescence of the product, the proposed method can thus be considered as a stability indicating assay for nicardipine, nifedipine and isradipine.
Conclusion
A simple and sensitive fluorimetric method based on the presence of the dihydrpyridine ring has been developed for the determination of nicardipine, nifedipine and isradipine after reduction of the nitro group into the fluorescence enhancing amino group. The fluorescence intensity-concentration plots of nicardipine, nifedipine and isradipine were rectilinear over the ranges 0.4-6.0, 0.2-4.0 and 0.1-9.0 μg ml -1 with detection limits of 0.0028, 0.017 and 0.016 μg ml -1 , respectively. The high sensitivity of the method allowed the drug determination in spiked human plasma and urine. Moreover, the proposed method was applied to urine analysis without prior extraction indicating no interference from the endogenous component and thus revealing high specificity of the proposed method. The detection limits is comparable to those given by the chromatographic methods. Table 4 . Application of the proposed spectrofluorimetric determination of studied compounds in spiked human urine and plasma.
* The average of three trials.
